Phase 2 Start
ASMB: Phase 2 Start: A Phase 2, Multicenter, Open Label, Parallel-Group Study of the Safety, Pharmacokinetics, and Effica
October 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 1, 2026
- Company
- ASSEMBLY BIOSCIENCES, INC. (ASMB)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Start~month
Phase 2 Start: A Phase 2, Multicenter, Open Label, Parallel-Group Study of the Safety, Pharmacokinetics, and Effica
- Indication
- Chronic Hepatitis D Infection